Early postnatal dexamethasone treatment and increased incidence of cerebral palsy

E S Shinwell; M Karplus; D Reich; Z Weintraub; S Blazer; D Bader; S Yurman; T Dolfin; A Kogan; S Dollberg; E Arbel; M Goldberg; I Gur; N Naor; L Sirota; S Mogilner; A Zaritsky; M Barak; E Gottfried

doi:10.1136/fn.83.3.F177

Responses

Original article

Early postnatal dexamethasone treatment and increased incidence of cerebral palsy

Compose a Response to This Article

Compose Response

Title *

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

PLEASE NOTE:

A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.

I agree to and have read the terms and conditions for rapid responses and BMJ Privacy Notice *

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

Re: Dexamethasone treatment and cerebral palsy
Eric S Shinwell
Published on: 9 January 2022
Dexamethasone treatment and cerebral palsy
POD Pharoah
Published on: 9 January 2022

Published on: 9 January 2022
Re: Dexamethasone treatment and cerebral palsy
- Eric S Shinwell, Neonatologist
Dear Editor,
We appreciate Dr Pharoah's comments on the definitions of incidence and prevalence.[1] However, his interpretation of the data appears erroneous.[2]
Dr Pharoah suggests that perhaps the dexamethasone-treated infants were sicker than the control infants and were saved by the intervention only to go on to suffer from cerebral palsy. This interpretation is incompatible with the data. There were...
Show More

Dear Editor,
We appreciate Dr Pharoah's comments on the definitions of incidence and prevalence.[1] However, his interpretation of the data appears erroneous.[2]
Dr Pharoah suggests that perhaps the dexamethasone-treated infants were sicker than the control infants and were saved by the intervention only to go on to suffer from cerebral palsy. This interpretation is incompatible with the data. There were no differences in the prenatal characteristics, delivery type or severity of disease after birth between the groups. There was no evidence to suggest that dexamethasone improves survival as has been borne out by other studies.
In addition, Dr Pharoah points to the infant who had cerebral palsy with normal ultrasound scans. The most likely explanation of these findings is that ultrasound has inadequate sensitivity in order to detect subtle fidings which may be picked up by other methods such as MRI.
Thus, our study does not address issues of prenatal timing of the pathogenesis of cerebral palsy, but rather points to a serious and potentially preventable postnatal cause.
References
(1) Pharoah POD. Dexamethasone treatment and cerebral palsy [Rapid Response]. http://adc.bmjjournals.com/cgi/eletters/fetalneonatal;83/3/F177#EL1 (8 November 2000)
(2) Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000;83:F177-81.
Show Less

Conflict of Interest:
None declared.
- Back to top
Published on: 9 January 2022
Dexamethasone treatment and cerebral palsy
- POD Pharoah, University teacher
Dear Editor,
Both the title of this paper and the first paragraph of the discussion imply that the use of postnatal dexamethasone may lead to cerebral palsy. However, it is the misuse of the term "incidence" that gives rise to this interpretation. The authors did not, neither could they, provide incidence data. What they presented was cerebral palsy prevalence data.
If it is accepted that prevalence and no...
Show More

Dear Editor,
Both the title of this paper and the first paragraph of the discussion imply that the use of postnatal dexamethasone may lead to cerebral palsy. However, it is the misuse of the term "incidence" that gives rise to this interpretation. The authors did not, neither could they, provide incidence data. What they presented was cerebral palsy prevalence data.
If it is accepted that prevalence and not incidence data are provided, then a very different interpretation of the findings can be made. Supposing the cerebral impairment of cerebral palsy occurred prepartum, then the use of dexamethasone may have allowed these children to survive whereas, had they received the placebo, they would have died before a diagnosis of cerebral palsy could be made. This would account for the higher prevalence of cerebral palsy in the dexamethasone compared with the placebo group. Support for this interpretation comes from the author's statement:
Eleven (22%) of the 51 children with cerebral palsy had normal neonatal ultrasound scans. All 11 of these infants were treated with dexamethasone.
This suggests that the cerebral impairment was prenatal in timing. Further support comes from the observation that there were fewer IVH in the dexamethasone group, although the difference did not quite attain the conventional level of statistical significance.
It needs to be appreciated that:
Prevalence = Incidence x Duration of disease.
The duration of the disease is affected by how long the child (or fetus) survives. Unless it is known what happens to the fetus from the time of conception, it is not possible to determine incidence in those diseases that have their origin during uterine development.
Professor Emeritus
POD Pharoah
Show Less

Conflict of Interest:
None declared.
- Back to top

Main menu

Plain text

PLEASE NOTE:

Vertical Tabs

Other responses

Jump to comment:

Log in using your username and password

Main menu

Log in using your username and password

You are here

Plain text

PLEASE NOTE:

Vertical Tabs

Other responses

Jump to comment:

Read the full text or download the PDF:

Log in using your username and password